94994-39-5

Basic information

• Product Name: 4-[(TERT-BUTOXYCARBONYL)(METHYL)AMINO]BUTANOIC ACID
• Synonyms: 4-[(TERT-BUTOXYCARBONYL)(METHYL)AMINO]BUTANOIC ACID;4-[N-Boc-(methylamino)]butanoic acid;4-(N-BOC-N-METHYL-AMINO)-BUTYRIC ACID;(Tert-Butoxy)Carbonyl N-Me-Abu(4)-OH;Boc-N-methyl-gamma-aminobutyric acid
• CAS NO: 94994-39-5
• Molecular Formula: C₁₀H₁₉NO₄
• Molecular Weight: 217.26216
• Mol File: 94994-39-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 332.5±21.0 °C(Predicted)
• Appearance: /
• Density: 1.091±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.70±0.10(Predicted)
• CAS DataBase Reference: 4-[(TERT-BUTOXYCARBONYL)(METHYL)AMINO]BUTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(TERT-BUTOXYCARBONYL)(METHYL)AMINO]BUTANOIC ACID(94994-39-5)
• EPA Substance Registry System: 4-[(TERT-BUTOXYCARBONYL)(METHYL)AMINO]BUTANOIC ACID(94994-39-5)

Safety Data

• Hazardous Substances Data: 94994-39-5(Hazardous Substances Data)

Usage

Uses

4-((tert-Butoxycarbonyl)(methyl)amino)butanoic Acid is used in preparation of substituted straight chain spiro derivatives as menin/MLL protein/protein interaction inhibitors useful for treating diseases.

Upstream product

• 1119-48-8 4-(methylamino)butyric acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 57294-38-9 N-(tert-butoxycarbonyl)-4-aminobutanoic acid 
• 74-88-4 methyl iodide 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 6976-17-6 4-(methylamino)butyric acid hydrochloride 
• 133171-74-1 methyl 4-[[(1,1-dimethylethoxy)carbonyl]methylamino]butanoic acid 

Downstream Products

• 95018-02-3 methyl N^a-(benzyloxycarbonyl)<thio>-L-cysteinate 
• 99207-32-6 4-(N-tert-Butyloxycarbonyl-N-methylamino)butanol 
• 120984-59-0 tert-butyl methyl-(4-oxo-butyl)-carbamate 
• 799279-16-6 1-[(tert-butoxycarbonyl)-N-methyl]amino-6-(4-phenoxyphenyl)hexane-4,6-dione 
• 1075748-33-2 [3-(2-amino-3-nitrophenylcarbamoyl)propyl]methylcarbamic acid tert.-butyl ester 
• 1052648-34-6 5-(2-amino-6-{2-[4-(tert-butoxycarbonylmethylamino)butyrylamino]ethylsulfanyl}pyrimidin-4-yl)-2-methoxy-4-methylbenzoic acid methyl ester 
• 876016-45-4 C₂₅H₃₁N₃O₄ 
• 1253582-08-9 {3-[3-(2-{benzyl-[(R)-2-(8-benzyloxy-2-oxo-1,2-dihydroquinolin-5-yl)-2-(tert-butyldimethylsilanyloxy)ethyl]amino}ethyl)phenylcarbamoyl]-propyl}methylcarbamic acid tert-butyl ester 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 1290070-54-0 C₂HF₃O₂*C₁₁H₁₅NO₂ 
• 1290070-21-1 C₁₆H₂₃NO₄ 
• 1538609-66-3 {3-[6-[2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-7-methyl-8-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamoyl]-propyl}-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES

Provided herein are pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

ANTIBODY DRUG CONJUGATES

The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof. Formula (I):

AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME

The invention relates to novel azacarbonlines having formula (I), wherein: R3, R4 represent independently H; hal; CF3; substituted oxy, optionally substituted alkoxy; optionally substituted amino; substituted carbonyl; optionally substituted carboxyl; optionally substituted amide; sulphur, such as optionally substituted sulphones, sulphoxides or sulphides; linear, branched or cyclic C1-C10 alkyl optionally comprising an optionally substituted heteroatom; optionally substituted linear, branched or cyclic C2-C7 alkenyl; optionally substituted linear or branched C2-C6 alkynyl; optionally substituted aryl or heteroaryl; of which may be optionally substituted; in the form of a base or an acid addition salt. The invention also relates to the use of same in therapeutics for the treatment of cancer and to synthesis methods.